Galmed Pharmaceuticals (NASDAQ:GLMD) Now Covered by StockNews.com
Analysts at StockNews.com started coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) in a research report issued on Thursday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock. Separately, Maxim Group reaffirmed a “hold” rating on shares of Galmed Pharmaceuticals in a research report on Friday, April 4th. Get Our […]
Analysts at StockNews.com started coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) in a research report issued on Thursday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock. Separately, Maxim Group reaffirmed a “hold” rating on shares of Galmed Pharmaceuticals in a research report on Friday, April 4th. Get Our […]
